Christopher Pearson, O.D.
Optometrists (Optometrist)
- Medicare participating
At a glance
- Medical school
- Southern College of Optometry (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 93
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: Southern College of Optometry
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Optometrist primary
FL license OPC 3672 -
Corneal and Contact Management Optometrist
FL license OPC 3672 -
Pediatric Optometrist
FL license OPC 3672
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Omega Vision Center PA (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 93
- Services billed
- 145
- Patients’ average age
- 76
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Latanoprost Other prescribers in Longwood, FL | 28 |
| Timolol Maleate Other prescribers in Longwood, FL | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 10 payments worth $737 in total to this clinician.
| Coopervision Inc. | $222 |
|---|---|
| Alcon Vision LLC | $150 |
| Bausch & Lomb Americas Inc. | $133 |
| Tarsus Pharmaceuticals, Inc. | $122 |
| Rxsight Inc | $110 |
| Food and Beverage | $737 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 3 companies. The companies reported $683,682 in research payments for these studies, mostly to the institutions running them.
- Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances
Oyster Point Pharma, Inc. · Completed · NCT06349759 - Pilot clinical evaluation of approved and investigational contact lenses
Johnson & Johnson Vision Care, Inc. - Clinical Evaluation of Soft Contact Lenses
Alcon Research LLC - Clinical Evaluation of Overall Lens Fit of Delefilcon A Contact Lenses of Different Diameters and Base Curves
Alcon Research LLC - Pilot Dispensing Study of Two Marketed Daily Disposable Multifocal Contact Lenses
Johnson & Johnson Vision Care, Inc. - Clinical evaluation of investigational contact lenses
Johnson & Johnson Vision Care, Inc. - Evaluating myopia progression after discontinuation of a soft contact lens for myopia control
Johnson & Johnson Vision Care, Inc. - Evaluation of Delefilcon A and Senofilcon A Daily Disposable Toric Soft Contact Lenses Over One Week of WearNCT06749496
Johnson & Johnson Vision Care, Inc. - Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia
Oyster Point Pharma, Inc. · Completed · NCT06542497 - Clinical Evaluation of a New Silicone Monomer
Johnson & Johnson Vision Care, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.